Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mocertatug rezetecan combination study in advanced solid tumors
NL-OMON59015Phase 2Recruiting
- Sponsor
- GSK
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of mocertatug rezetecan in Nonhematologic neoplasms and gynecological cancer (2 arms), sponsored by GSK. Primary endpoints: Dose-limiting toxicities, Safety and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
mocertatug rezetecan
03
Conditions
Nonhematologic neoplasmsgynecological cancer
Beyond the preview
Go deeper on NL-OMON59015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59015.